← boardnext 2026-09next 2027-06next 2027-08
LNTH
Lantheus Biosciences Ltd.distress 0/10 · well-funded / low risk$101.48-3%today-9% from 52w high
Cardiovascular 1
Lead: Relapsed / Refractory Osteosarcoma
Revenue
$377M
Liquidity
$499M
Runway
—
Shares 1y
-4%
Price & events
+51.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
-3.4%
1W
-4.3%
1M
+22.5%
3M
+50.3%
6M
+38.4%
1Y
-12.2%
2Y
+295.3%
5Y
+637.0%
All
Overview
- Market Cap
- $6.61B
- Volume
- 49.35K
- 52 Week Range
- $50.11 – $111
- Total Shares
- 65.11M
- Float Shares
- 58.36M
- Short %
- 12.95%
- % Held by Insiders
- 2.09%
- % Held by Institutions
- 116.40%
- RVOL
- 0.05x
- Beta
- -0.06
Pipeline stages · 3 programs
Florbetaben F18
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
[18F]PI-2620
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-01 | Phase 1 | Florbetaben F18 | Cardiac Amyloidosis | 15 | recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | [18F]PI-2620 | Alzheimer Disease | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D) | Relapsed / Refractory Osteosarcoma | — | recruiting |
Catalyst news & presentations · 8
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- March 6, 2026PDUFAPDUFApiflufolastat F-18 (new formulation) · PDUFA date for new formulation of piflufolastat F-18 PSMA PET imaging agent.SEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)Closing of acquisition of Life MolecularSEC 8-K
- 2025-07-21partnershipAcquisition of Life Molecular Imaging completed.SEC 8-K
- 2025-04-01partnershipLantheus completed acquisition of Evergreen Theragnostics, gaining OCTEVY and manufacturing infrastructure.SEC 8-K
- 2025-01-27partnershipLantheus Medical signed a merger agreement to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones.SEC 8-K
- 2025-01-12partnershipNeuraceq · Lantheus subsidiary to acquire Life Molecular for $350M upfront plus up to $430M in earnouts and milestone payments.SEC 8-K
- October 2024readoutPhase 3177Lu-PNT2002 · Data release based on 75% of protocol-specified target overall survival events reachedSEC 8-K
Approved drugs (1)
- NEURACEQFLORBETABEN F-182014 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $112 (+10% upside) · 12 analysts
- 2026-07-16Truist SecuritiesBuy
- 2026-07-15MizuhoOutperform → Market Outperform
- 2026-07-09B. Riley SecuritiesBuy
- 2026-06-29CitizensMarket Outperform
- 2026-05-27MizuhoOutperform
- 2026-05-11Truist SecuritiesBuy
Competitors — Relapsed / Refractory Osteosarcoma
- none identified
Recent news
- 2026-07-23Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time - The Manila Times
- 2026-07-22Lantheus Holdings Inc (LNTH) Shares Surge 3.4% -- What GF Score of 80 Tells Investors - GuruFocus
- 2026-07-21Lantheus Holdings Inc (LNTH) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-20LNTH News | LANTHEUS HOLDINGS INC (NASDAQ:LNTH) - ChartMill
- 2026-07-20Lantheus Holdings (NASDAQ:LNTH) Is a High-Quality Technical Breakout Setup - ChartMill
- 2026-07-20Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 23.48% ROE in the Healthcare Sector - DirectorsTalk Interviews
- 2026-07-19(LNTH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
- 2026-07-16Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating, Announces Target Price $125 - 富途牛牛
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.